US · AUPH
Aurinia Pharmaceuticals Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Edmonton, BC V8Z 7X8
- Website
- auriniapharma.com
Price · as of 2025-12-31
$15.35
Market cap 1.87B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $43.31 | +182.15% |
| Intrinsic Value(DCF) | $78.12 | +408.93% |
| Graham-Dodd Method(GD) | $15.01 | -2.19% |
| Graham Formula(GF) | $59.09 | +284.93% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.00 | $42.80 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.09 | $29.21 | |||
| 2014 | $4.48 | $26.01 | $0.80 | $0.00 | $34.11 |
| 2015 | $2.63 | $25.11 | $0.00 | $0.00 | $3.82 |
| 2016 | $8.50 | $28.85 | $0.30 | $0.00 | $11.30 |
| 2017 | $5.54 | $40.44 | $1.42 | $0.00 | $0.00 |
| 2018 | $6.38 | $26.45 | $0.58 | $0.00 | $0.00 |
| 2019 | $16.86 | $32.65 | $2.05 | $0.00 | $20.81 |
| 2020 | $13.76 | $2,382.01 | $3.51 | $0.00 | $0.00 |
| 2021 | $10.62 | $25.49 | $2.11 | $0.00 | $0.67 |
| 2022 | $8.79 | $48.43 | $17,063.73 | $0.00 | $0.00 |
| 2023 | $5.43 | $29.72 | $521.80 | $0.00 | $0.00 |
| 2024 | $8.15 | $43.69 | $975.83 | $2.84 | $1.64 |
| 2025 | $14.21 | $43.31 | $208.25 | $15.01 | $59.09 |
AI valuation
Our deep-learning model estimates Aurinia Pharmaceuticals Inc.'s (AUPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $43.31
- Current price
- $15.35
- AI upside
- +182.15%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$78.12
+408.93% upside
Graham-Dodd
$15.01
-2.19% upside
Graham Formula
$59.09
+284.93% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AUPH | Aurinia Pharmaceuticals I… | $15.35 | 1.87B | +182% | +409% | -2% | +285% | 6.65 | 3.28 | 6.75 | 12.42 | 0.13 | 3.31 | 88.46% | 37.06% | 101.47% | 59.91% | 58.85% | 44.11% | 0.13 | 24.23 | 5.25 | 4.69 | -0.04 | 516718.00% | 2038.00% | 20699.00% | 7.09% | 1.45 | 75.96% | 0.00% | 0.00% | 5.21% | 15.12 | 11.71 | 5.60 | 6.99 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| CLDX | Celldex Therapeutics, Inc… | $30.09 | 2B | +2% | -54% | — | +767% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| HRMY | Harmony Biosciences Holdi… | $28.54 | 1.64B | +155% | +609% | +1% | +178% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| IMCR | Immunocore Holdings plc | $32.30 | 1.64B | +113% | -48% | -85% | — | -46.31 | 4.32 | 5.53 | 2128.75 | — | 4.32 | 97.91% | -11.34% | -8.88% | -9.58% | 14.46% | -3.42% | 0.11 | -2.77 | 4.04 | 3.80 | -1095.49 | -4804.00% | 2010.00% | -15893.00% | -0.75% | -0.03 | 5.28% | 0.00% | 0.00% | 24.39% | -24.43 | -66.96 | 2.77 | 1.37 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| MNKD | MannKind Corporation | $3.28 | 1.01B | +882% | +28% | — | -83% | 158.21 | -18.18 | 2.66 | 29.19 | — | -7.50 | 82.47% | 11.12% | 1.68% | -9.03% | -19.22% | 0.99% | -0.92 | 2.81 | 1.70 | 1.23 | -1.01 | -7942.00% | 2223.00% | -5829.00% | 1.48% | 0.11 | -6.78% | 0.00% | 0.00% | 3.16% | 20.70 | 58.68 | 2.30 | -4.20 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| STOK | Stoke Therapeutics, Inc. | $36.41 | 2.08B | +35% | +5,275% | — | — | -4.86 | 1.89 | 11.83 | -2.20 | — | 1.89 | 100.00% | -277.31% | -243.42% | -45.80% | 800.63% | -35.60% | 0.01 | — | 5.81 | 5.43 | 1.27 | -3067.00% | 31634.00% | 529.00% | -20.12% | -2.17 | 687.55% | 0.00% | 0.00% | 0.00% | -2.15 | -2.50 | 5.96 | 3.33 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
- CEO
- Peter S. Greenleaf
- Employees
- 130
- Beta
- 1.51
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($78.12 ÷ $15.35) − 1 = +408.93% (DCF, example).